本帖最后由 老马 于 2012-1-13 21:20 编辑
; M# y& s2 c6 P( v- V+ w7 i2 n
: q0 q- d: T0 D- K3 ~3 X" d爱必妥和阿瓦斯丁的比较
. _+ o7 g: }: e. \, N
3 ~ E/ N7 |3 n0 |; t; J6 J
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/
_. e2 D6 n- I: g' B# K- J
+ X- i- O0 P8 X( @ t, z* w9 r/ Q! F
/ g& f5 a; E* x& e( vhttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/) @; j/ f* U; b" a
==================================================% }) \; N# ]$ H' x) ?. ~
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
: i+ }+ C8 k2 z" N7 }Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.( _3 J6 c9 A4 M5 u1 p6 W
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.0 M6 P. g& x/ t
|